PT2379067E - Regime de dosagem para fingolimod para o tratamento de esclerose múltipla - Google Patents

Regime de dosagem para fingolimod para o tratamento de esclerose múltipla Download PDF

Info

Publication number: PT2379067E
Authority: PT; Portugal
Prior art keywords: fingolimod; treatment; multiple sclerosis; dosage regimen; regimen
Prior art date: 2008-12-22

Application number

PT97972343T

Other languages

English (en)

Inventor

Robert Schmouder

Thomas Dumortier

Olivier David

Michael Looby

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-22

Filing date

2009-12-21

Publication date

2015-12-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2379067(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-21 Application filed by Novartis Ag filed Critical Novartis Ag

2015-12-23 Publication of PT2379067E publication Critical patent/PT2379067E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT97972343T 2008-12-22 2009-12-21 Regime de dosagem para fingolimod para o tratamento de esclerose múltipla PT2379067E (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US13967208P	2008-12-22	2008-12-22
US21853009P	2009-06-19	2009-06-19
US24671509P	2009-09-29	2009-09-29

Publications (1)

Publication Number	Publication Date
PT2379067E true PT2379067E (pt)	2015-12-23

Family

ID=41667217

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PT182010629T PT3453387T (pt)	2008-12-22	2009-12-21	Regime de dosagem para um agonista do recetor s1p
PT181793019T PT3409274T (pt)	2008-12-22	2009-12-21	Regime de dosagem para um agonista de recetor de s1p
PT97972343T PT2379067E (pt)	2008-12-22	2009-12-21	Regime de dosagem para fingolimod para o tratamento de esclerose múltipla
PT221870074T PT4098256T (pt)	2008-12-22	2009-12-21	Regime de dosagem para um agonista do recetor de s1p

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PT182010629T PT3453387T (pt)	2008-12-22	2009-12-21	Regime de dosagem para um agonista do recetor s1p
PT181793019T PT3409274T (pt)	2008-12-22	2009-12-21	Regime de dosagem para um agonista de recetor de s1p

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT221870074T PT4098256T (pt)	2008-12-22	2009-12-21	Regime de dosagem para um agonista do recetor de s1p

Country Status (43)

Country	Link
US (12)	US20100160259A1 (pt)
EP (7)	EP3453387B1 (pt)
JP (7)	JP2012513401A (pt)
KR (1)	KR101347919B1 (pt)
CN (1)	CN102264359A (pt)
AR (1)	AR074826A1 (pt)
AU (1)	AU2009330176C9 (pt)
BR (1)	BRPI0923500A2 (pt)
CA (1)	CA2747802C (pt)
CL (2)	CL2011001529A1 (pt)
CO (1)	CO6390117A2 (pt)
CR (1)	CR20110274A (pt)
CU (1)	CU20110136A7 (pt)
CY (4)	CY1116990T1 (pt)
DK (4)	DK3453387T3 (pt)
EA (1)	EA201100978A1 (pt)
EC (1)	ECSP11011222A (pt)
ES (4)	ES2552823T3 (pt)
FI (2)	FI4098256T3 (pt)
FR (2)	FR20C1060I1 (pt)
HN (1)	HN2011001759A (pt)
HR (4)	HRP20250568T1 (pt)
HU (6)	HUE048717T4 (pt)
IL (3)	IL213170A0 (pt)
LT (5)	LT3409274T (pt)
LU (1)	LUC00183I2 (pt)
MA (1)	MA32981B1 (pt)
ME (2)	ME03802B (pt)
MX (3)	MX385959B (pt)
NO (1)	NO2020038I1 (pt)
NZ (1)	NZ593065A (pt)
PE (1)	PE20120337A1 (pt)
PL (4)	PL4098256T3 (pt)
PT (4)	PT3453387T (pt)
RS (3)	RS66784B9 (pt)
SG (1)	SG171404A1 (pt)
SI (4)	SI3453387T1 (pt)
SM (2)	SMT202000441T1 (pt)
TN (1)	TN2011000272A1 (pt)
TW (1)	TW201028143A (pt)
UY (1)	UY32352A (pt)
WO (1)	WO2010075239A1 (pt)
ZA (2)	ZA201103863B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2278960T4 (da)	2008-03-17	2020-01-27	Actelion Pharmaceuticals Ltd	Dosisregimen til en selektiv sip1 receptoragonist
ES2552823T3 (es)	2008-12-22	2015-12-02	Novartis Ag	Régimen de dosificación para fingolimod para el tratamiento de la esclerosis múltiple
BR112012006957A2 (pt)	2009-09-29	2016-06-14	Novartis Ag	regime de dosagem de um modulador de receptor de s1p
US20110124605A1 (en) *	2009-11-20	2011-05-26	Shreeram Aradhye	Use of an S1P Receptor Agonist
SG10201500639TA (en)	2010-01-27	2015-03-30	Arena Pharm Inc	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
EA201201515A1 (ru) *	2010-05-06	2013-08-30	Новартис Аг	Схема приема производных диарилсульфидов
EP2455080A1 (en) *	2010-11-23	2012-05-23	Almirall, S.A.	S1P1 receptor agonists for use in the treatment of multiple sclerosis
FR2968556B1 (fr)	2010-12-13	2013-12-27	Centre Nat Rech Scient	Inhibiteurs des infections a vih et leurs utilisations
MA34897B1 (fr)	2011-01-07	2014-02-01	Novartis Ag	Formulations d'immunosupresseurs
DK2675893T3 (en)	2011-02-18	2019-04-15	Scripps Research Inst	Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
JO3177B1 (ar)	2011-04-01	2018-03-08	Novartis Ag	تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
US9592268B2 (en)	2011-05-23	2017-03-14	Cornell University	Endothelium protective materials and methods of use
TW201320994A (zh) *	2011-10-11	2013-06-01	Novartis Ag	投藥療程
SMT202000298T1 (it)	2012-08-17	2020-07-08	Actelion Pharmaceuticals Ltd	Processo per la produzione di (2z,5z)-5-(3-cloro-4((r)-2,3-diidrossipropossi) benziliden)-2-(propilimmino)-3-(o-tolil)tiazolidin-4-one e intermedio usato in detto processo
US20160129084A1 (en) *	2013-03-06	2016-05-12	Acorda Therapeutics, Inc.	Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
EP3054933A4 (en)	2013-10-11	2017-03-15	Teikoku Pharma USA, Inc.	Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
WO2015053879A1 (en)	2013-10-11	2015-04-16	Teikoku Pharma Usa, Inc.	Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
RU2020107732A (ru) *	2014-04-10	2020-03-30	Новартис Аг	Схема дозирования модулятора s1p с немедленным высвобождением
PL3256125T3 (pl)	2014-12-11	2022-05-09	Actelion Pharmaceuticals Ltd	Schemat dawkowania ponesimodu, selektywnego agonisty receptora s1p1
MA41139A (fr)	2014-12-11	2017-10-17	Actelion Pharmaceuticals Ltd	Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
PL3242666T3 (pl) *	2015-01-06	2025-02-17	Arena Pharmaceuticals, Inc.	Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
WO2016135644A1 (en)	2015-02-26	2016-09-01	Novartis Ag	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
JP6838744B2 (ja)	2015-06-22	2021-03-03	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
AU2018220521A1 (en)	2017-02-16	2019-09-05	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
CA3053416A1 (en)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
KR102859841B1 (ko)	2018-06-06	2025-09-12	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 병태의 치료 방법
WO2021084068A1 (en)	2019-10-31	2021-05-06	Idorsia Pharmaceuticals Ltd	Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021158838A1 (en)	2020-02-07	2021-08-12	Argentum Pharmaceuticals Llc	Dosage regimen of an s1p receptor modulator
WO2021158848A1 (en) *	2020-02-07	2021-08-12	Argentum Pharmaceuticals Llc	Dosage regimen of an s1p receptor agonist
CA3169569A1 (en) *	2020-02-28	2021-09-02	Damian Grobelny	S1p receptor modulators
CN113332435B (zh) *	2021-06-18	2022-10-18	广州中医药大学(广州中医药研究院)	鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0155015B1 (ko)	1992-10-21	1998-12-01	고우야 마사시	2-아미노-1,3-프로판디올 화합물 및 면역 억제제
CA2421893A1 (en)	2000-08-31	2002-03-07	Merck And Co., Inc.	Phosphate derivatives as immunoregulatory agents
KR20120125398A (ko)	2002-05-16	2012-11-14	노파르티스 아게	암에서 ｅｄｇ 수용체 결합제의 용도
JP4861177B2 (ja) *	2003-09-12	2012-01-25	ニューロノバエービー	神経系の障害の処置
US20060002999A1 (en) *	2004-06-17	2006-01-05	Forest Laboratories, Inc.	Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
ES2495690T3 (es) *	2004-11-29	2014-09-17	Novartis Ag	Régimen de dosificación de un agonista del receptor S1P
EP1688141A1 (en) *	2005-01-31	2006-08-09	elbion AG	The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
WO2006085316A2 (en) *	2005-02-10	2006-08-17	G.I. View Ltd.	Advancement techniques for gastrointestinal tool with guiding element
EP2465492B1 (en) *	2007-10-12	2015-07-01	Novartis AG	Compositions comprising sphingosine I phosphate (sip) receptor modulators
DK2278960T4 (da) *	2008-03-17	2020-01-27	Actelion Pharmaceuticals Ltd	Dosisregimen til en selektiv sip1 receptoragonist
JP2011525189A (ja) *	2008-06-20	2011-09-15	ノバルティスアーゲー	多発性硬化症を治療するための小児科の組成物
AR074825A1 (es)	2008-12-22	2011-02-16	Novartis Ag	Regimen de dosificacion de un agonista de los receptores de s1p, metodo de tratamiento y kit
ES2552823T3 (es)	2008-12-22	2015-12-02	Novartis Ag	Régimen de dosificación para fingolimod para el tratamiento de la esclerosis múltiple

2009
- 2009-12-21 ES ES09797234.3T patent/ES2552823T3/es active Active
- 2009-12-21 CA CA2747802A patent/CA2747802C/en active Active
- 2009-12-21 SI SI200932080T patent/SI3453387T1/sl unknown
- 2009-12-21 HU HUE18179301A patent/HUE048717T4/hu unknown
- 2009-12-21 HR HRP20250568TT patent/HRP20250568T1/hr unknown
- 2009-12-21 RS RS20250452A patent/RS66784B9/sr unknown
- 2009-12-21 KR KR1020117017073A patent/KR101347919B1/ko active Active
- 2009-12-21 RS RS20191546A patent/RS59857B1/sr unknown
- 2009-12-21 DK DK18201062.9T patent/DK3453387T3/da active
- 2009-12-21 AU AU2009330176A patent/AU2009330176C9/en not_active Withdrawn - After Issue
- 2009-12-21 ME MEP-2020-156A patent/ME03802B/me unknown
- 2009-12-21 MX MX2018006099A patent/MX385959B/es unknown
- 2009-12-21 HU HUE18201062A patent/HUE052048T2/hu unknown
- 2009-12-21 PL PL22187007.4T patent/PL4098256T3/pl unknown
- 2009-12-21 TW TW098143960A patent/TW201028143A/zh unknown
- 2009-12-21 JP JP2011542521A patent/JP2012513401A/ja not_active Withdrawn
- 2009-12-21 PT PT182010629T patent/PT3453387T/pt unknown
- 2009-12-21 NZ NZ593065A patent/NZ593065A/xx not_active IP Right Cessation
- 2009-12-21 PT PT181793019T patent/PT3409274T/pt unknown
- 2009-12-21 PL PL18201062T patent/PL3453387T3/pl unknown
- 2009-12-21 EP EP18201062.9A patent/EP3453387B1/en active Active
- 2009-12-21 SM SM20200441T patent/SMT202000441T1/it unknown
- 2009-12-21 EP EP22187007.4A patent/EP4098256B9/en active Active
- 2009-12-21 LT LTEP18179301.9T patent/LT3409274T/lt unknown
- 2009-12-21 MA MA34034A patent/MA32981B1/fr unknown
- 2009-12-21 DK DK22187007.4T patent/DK4098256T5/da active
- 2009-12-21 PE PE2011001265A patent/PE20120337A1/es not_active Application Discontinuation
- 2009-12-21 US US12/642,892 patent/US20100160259A1/en not_active Abandoned
- 2009-12-21 ES ES18201062T patent/ES2810823T3/es active Active
- 2009-12-21 ES ES18179301T patent/ES2760607T3/es active Active
- 2009-12-21 PT PT97972343T patent/PT2379067E/pt unknown
- 2009-12-21 ES ES22187007T patent/ES3017254T3/es active Active
- 2009-12-21 RS RS20200900A patent/RS60666B1/sr unknown
- 2009-12-21 SG SG2011037629A patent/SG171404A1/en unknown
- 2009-12-21 SI SI200932211T patent/SI4098256T1/sl unknown
- 2009-12-21 BR BRPI0923500-0A patent/BRPI0923500A2/pt not_active Application Discontinuation
- 2009-12-21 DK DK18179301.9T patent/DK3409274T3/da active
- 2009-12-21 FI FIEP22187007.4T patent/FI4098256T3/fi active
- 2009-12-21 EP EP16182876.9A patent/EP3120844A1/en not_active Withdrawn
- 2009-12-21 EP EP20160225.7A patent/EP3677260A1/en active Pending
- 2009-12-21 UY UY0001032352A patent/UY32352A/es not_active Application Discontinuation
- 2009-12-21 ME MEP-2019-339A patent/ME03594B/me unknown
- 2009-12-21 LT LTEP22187007.4T patent/LT4098256T/lt unknown
- 2009-12-21 SM SM20200054T patent/SMT202000054T1/it unknown
- 2009-12-21 AR ARP090105010A patent/AR074826A1/es not_active Application Discontinuation
- 2009-12-21 SI SI200931311T patent/SI2379067T1/sl unknown
- 2009-12-21 PT PT221870074T patent/PT4098256T/pt unknown
- 2009-12-21 EP EP18179301.9A patent/EP3409274B1/en not_active Revoked
- 2009-12-21 US US13/141,552 patent/US20110257133A1/en not_active Abandoned
- 2009-12-21 PL PL09797234T patent/PL2379067T3/pl unknown
- 2009-12-21 PL PL18179301T patent/PL3409274T3/pl unknown
- 2009-12-21 WO PCT/US2009/068888 patent/WO2010075239A1/en not_active Ceased
- 2009-12-21 EP EP09797234.3A patent/EP2379067B1/en not_active Revoked
- 2009-12-21 EA EA201100978A patent/EA201100978A1/ru unknown
- 2009-12-21 EP EP15158251.7A patent/EP2907511A1/en not_active Withdrawn
- 2009-12-21 CN CN2009801518640A patent/CN102264359A/zh active Pending
- 2009-12-21 HR HRP20151190TT patent/HRP20151190T1/hr unknown
- 2009-12-21 HU HUE09797234A patent/HUE026869T2/en unknown
- 2009-12-21 LT LTEP18201062.9T patent/LT3453387T/lt unknown
- 2009-12-21 DK DK09797234.3T patent/DK2379067T3/en active
- 2009-12-21 MX MX2011006623A patent/MX2011006623A/es unknown
- 2009-12-21 HU HUE22187007A patent/HUE071189T2/hu unknown
- 2009-12-21 SI SI200932015T patent/SI3409274T1/sl unknown
2011
- 2011-05-25 ZA ZA2011/03863A patent/ZA201103863B/en unknown
- 2011-05-25 CR CR20110274A patent/CR20110274A/es not_active Application Discontinuation
- 2011-05-26 IL IL213170A patent/IL213170A0/en unknown
- 2011-05-26 TN TN2011000272A patent/TN2011000272A1/fr unknown
- 2011-06-17 MX MX2021010759A patent/MX2021010759A/es unknown
- 2011-06-21 CL CL2011001529A patent/CL2011001529A1/es unknown
- 2011-06-22 CU CU20110136A patent/CU20110136A7/es unknown
- 2011-06-22 EC EC2011011222A patent/ECSP11011222A/es unknown
- 2011-06-22 HN HN2011001759A patent/HN2011001759A/es unknown
- 2011-06-23 CO CO11079290A patent/CO6390117A2/es not_active Application Discontinuation
2012
- 2012-08-06 ZA ZA2012/05942A patent/ZA201205942B/en unknown
2013
- 2013-05-31 CL CL2013001558A patent/CL2013001558A1/es unknown
- 2013-09-06 US US14/020,058 patent/US20140066657A1/en not_active Abandoned
2014
- 2014-01-31 US US14/169,660 patent/US20140148415A1/en not_active Abandoned
- 2014-04-10 JP JP2014080892A patent/JP2014144970A/ja not_active Withdrawn
2015
- 2015-10-14 JP JP2015202669A patent/JP2016135752A/ja not_active Withdrawn
- 2015-11-30 CY CY20151101084T patent/CY1116990T1/el unknown
- 2015-12-02 US US14/956,855 patent/US20160081949A1/en not_active Abandoned
2016
- 2016-05-23 US US15/161,778 patent/US20160263061A1/en not_active Abandoned
2017
- 2017-03-06 JP JP2017041331A patent/JP2017141238A/ja not_active Withdrawn
- 2017-03-21 US US15/465,091 patent/US20170189353A1/en not_active Abandoned
2018
- 2018-06-11 US US16/005,137 patent/US20180289638A1/en not_active Abandoned
- 2018-11-26 US US16/199,905 patent/US20190091180A1/en not_active Abandoned
2019
- 2019-05-22 JP JP2019095899A patent/JP7329965B2/ja active Active
- 2019-12-02 HR HRP20192175TT patent/HRP20192175T1/hr unknown
- 2019-12-03 CY CY20191101264T patent/CY1122812T1/el unknown
2020
- 2020-05-05 US US16/867,293 patent/US20200330407A1/en not_active Abandoned
- 2020-05-18 IL IL274756A patent/IL274756A/en unknown
- 2020-07-27 HR HRP20201167TT patent/HRP20201167T1/hr unknown
- 2020-08-03 CY CY20201100712T patent/CY1123255T1/el unknown
- 2020-11-17 LT LTPA2020005C patent/LTPA2020005I1/lt unknown
- 2020-11-17 LU LU00183C patent/LUC00183I2/fr unknown
- 2020-11-18 NO NO2020038C patent/NO2020038I1/no unknown
- 2020-11-19 FR FR20C1060C patent/FR20C1060I1/fr active Active
- 2020-11-19 CY CY2020036C patent/CY2020036I2/el unknown
- 2020-11-19 HU HUS2000046C patent/HUS2000046I1/hu unknown
- 2020-11-23 IL IL278914A patent/IL278914A/en unknown
2021
- 2021-09-20 US US17/479,649 patent/US20220142949A1/en not_active Abandoned
2022
- 2022-04-21 JP JP2022070231A patent/JP2022103194A/ja active Pending
2024
- 2024-06-06 JP JP2024092377A patent/JP2024129030A/ja active Pending
- 2024-09-27 US US18/900,154 patent/US20250262171A1/en active Pending
2025
- 2025-04-08 FR FR25C1012C patent/FR25C1012I1/fr active Active
- 2025-05-19 LT LTPA2025520C patent/LTPA2025520I1/lt unknown
- 2025-05-23 FI FIC20253002C patent/FIC20253002I1/fi unknown
- 2025-06-13 HU HUS2500026C patent/HUS2500026I1/hu unknown

Also Published As

Publication number	Publication date
HUE026869T2 (en)	2016-08-29
JP2012513401A (ja)	2012-06-14
SMT202000054T1 (it)	2020-03-13
JP2017141238A (ja)	2017-08-17
CL2013001558A1 (es)	2013-10-25
LT3453387T (lt)	2020-08-25
TN2011000272A1 (en)	2012-12-17
FR20C1060I1 (fr)	2020-12-25
AR074826A1 (es)	2011-02-16
US20250262171A1 (en)	2025-08-21
DK3409274T3 (da)	2019-12-16
DK2379067T3 (en)	2015-12-07
AU2009330176B2 (en)	2014-03-06
ZA201205942B (en)	2013-03-27
FIC20253002I1 (fi)	2025-05-23
AU2009330176A1 (en)	2011-07-07
CY1123255T1 (el)	2021-10-29
EP4098256B1 (en)	2025-02-26
JP2024129030A (ja)	2024-09-26
ME03802B (me)	2021-04-20
HUE052048T2 (hu)	2021-04-28
HRP20250568T1 (hr)	2025-07-04
SI3409274T1 (sl)	2020-03-31
PT3453387T (pt)	2020-08-11
LTPA2020005I1 (lt)	2020-12-10
AU2009330176C9 (en)	2017-01-05
HUE048717T2 (hu)	2020-08-28
IL213170A0 (en)	2011-07-31
HUE048717T4 (hu)	2022-02-28
HN2011001759A (es)	2013-11-26
EP3120844A1 (en)	2017-01-25
ECSP11011222A (es)	2011-08-31
RS66784B1 (sr)	2025-06-30
KR20110096175A (ko)	2011-08-29
ES3017254T3 (en)	2025-05-12
EP2379067A1 (en)	2011-10-26
MX385959B (es)	2025-03-18
US20110257133A1 (en)	2011-10-20
US20190091180A1 (en)	2019-03-28
MA32981B1 (fr)	2012-01-02
CY2020036I1 (el)	2021-03-12
DK3453387T3 (da)	2020-08-10
DK4098256T3 (da)	2025-04-22
HRP20192175T1 (hr)	2020-03-20
EP3409274A1 (en)	2018-12-05
DK4098256T5 (da)	2025-07-21
RS60666B1 (sr)	2020-09-30
SG171404A1 (en)	2011-07-28
US20180289638A1 (en)	2018-10-11
WO2010075239A1 (en)	2010-07-01
PL3453387T3 (pl)	2020-11-02
EA201100978A1 (ru)	2012-01-30
US20160263061A1 (en)	2016-09-15
US20220142949A1 (en)	2022-05-12
SI3453387T1 (sl)	2020-10-30
HUE071189T2 (hu)	2025-08-28
US20100160259A1 (en)	2010-06-24
EP3453387B1 (en)	2020-06-03
LTPA2025520I1 (pt)	2025-06-25
PL3409274T3 (pl)	2020-06-01
US20170189353A1 (en)	2017-07-06
US20140148415A1 (en)	2014-05-29
HRP20201167T1 (hr)	2020-12-11
UY32352A (es)	2010-07-30
PL2379067T3 (pl)	2016-02-29
LT3409274T (lt)	2020-02-10
EP4098256B9 (en)	2025-06-18
PT4098256T (pt)	2025-04-10
EP3409274B1 (en)	2019-11-20
NZ593065A (en)	2012-11-30
EP2907511A1 (en)	2015-08-19
SI4098256T1 (sl)	2025-06-30
EP3453387A1 (en)	2019-03-13
HUS2500026I1 (hu)	2025-07-28
JP2016135752A (ja)	2016-07-28
EP4098256A1 (en)	2022-12-07
IL274756A (en)	2020-07-30
JP2014144970A (ja)	2014-08-14
US20140066657A1 (en)	2014-03-06
AU2009330176C1 (en)	2016-12-08
MX2021010759A (es)	2022-07-19
CN102264359A (zh)	2011-11-30
HUS2000046I1 (hu)	2020-12-28
EP2379067B1 (en)	2015-09-02
US20160081949A1 (en)	2016-03-24
CA2747802A1 (en)	2010-07-01
SI2379067T1 (sl)	2016-01-29
LT4098256T (lt)	2025-06-10
CA2747802C (en)	2021-02-09
CY1122812T1 (el)	2021-05-05
JP7329965B2 (ja)	2023-08-21
CO6390117A2 (es)	2012-02-29
CL2011001529A1 (es)	2012-02-24
ME03594B (me)	2020-07-20
SMT202000441T1 (it)	2020-09-10
MX2011006623A (es)	2011-07-12
RS66784B9 (sr)	2025-08-29
HRP20151190T1 (hr)	2016-01-01
BRPI0923500A2 (pt)	2018-05-29
IL278914A (en)	2021-01-31
TW201028143A (en)	2010-08-01
ES2810823T3 (es)	2021-03-09
LUC00183I2 (pt)	2024-07-01
KR101347919B1 (ko)	2014-01-07
ZA201103863B (en)	2012-10-31
FR25C1012I1 (fr)	2025-06-13
FI4098256T3 (fi)	2025-03-31
EP3677260A1 (en)	2020-07-08
PE20120337A1 (es)	2012-04-24
NO2020038I1 (no)	2020-11-18
JP2022103194A (ja)	2022-07-07
CR20110274A (es)	2011-07-19
PT3409274T (pt)	2019-12-17
US20200330407A1 (en)	2020-10-22
JP2019167360A (ja)	2019-10-03
ES2552823T3 (es)	2015-12-02
CY2020036I2 (el)	2021-06-25
CU20110136A7 (es)	2012-01-31
PL4098256T3 (pl)	2025-06-09
RS59857B1 (sr)	2020-02-28
CY1116990T1 (el)	2017-04-05
ES2760607T3 (es)	2020-05-14

Publication	Publication Date	Title
PT2379067E (pt)	2015-12-23	Regime de dosagem para fingolimod para o tratamento de esclerose múltipla
TWI561257B (en)	2016-12-11	Extended release oral acetaminophen/tramadol dosage form
ZA201006029B (en)	2011-05-25	Pharmaceutical dosage form
PL2205273T3 (pl)	2017-09-29	Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
ZA201207068B (en)	2013-05-29	Formulations for oral delivery of adsorbents in the gut
ZA201109447B (en)	2012-08-29	Oxidation-stabilized tamper-resistant dosage form
IL264349B1 (en)	2023-09-01	Regimens containing neratinib for the treatment of cancer
PL2632889T3 (pl)	2019-04-30	Związki pośrednie i sposób wytwarzania fingolimodu
ZA201402907B (en)	2015-04-29	Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies
ZA201008222B (en)	2011-07-27	Process for the synthesis of arformoterol
ZA200903858B (en)	2013-10-30	Pharmaceutical dosage form
IL209360A (en)	2015-10-29	Medications containing pm00104 for the treatment of multiple myeloma
IL248919B (en)	2018-12-31	Pediatric compounds for the treatment of multiple sclerosis
GB0803054D0 (en)	2008-03-26	Medicament
IL200032A0 (en)	2010-04-15	Medicament for the treatment of endometriosis
GB0822124D0 (en)	2009-01-07	Oral dosage form
ZA201100163B (en)	2011-09-28	Unit dosage of apadenoson
PL2229943T3 (pl)	2012-11-30	Związek do zastosowania w leczeniu neuropatii obwodowych
EP2641609A4 (en)	2014-07-23	THERAPEUTIC AGENT FOR MUSCLE DYSTROPHY
GB0918912D0 (en)	2009-12-16	Improved medicament formulation
GB0802576D0 (en)	2008-03-19	Dosage form
PL394512A1 (pl)	2012-10-22	Srodek stomatologiczny przeznaczony do leczenia endodontycznego oraz sposób jago wytwarzania
IL226042A0 (en)	2013-06-27	Intermediates and methods for preparing fingolimod
GB0803395D0 (en)	2008-04-02	Medicament
IL215143A0 (en)	2011-12-29	Process for the preparation of alogliptin